Get the Stockscreener App
0.7344
0.74%
-0.0055
After Hours:
.74
0.0056
+0.76%
Tiziana Life Sciences Ltd stock is traded at $0.7344, with a volume of 156.97K.
It is down -0.74% in the last 24 hours and down -5.24% over the past month.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$0.7399
Open:
$0.75
24h Volume:
156.97K
Relative Volume:
0.44
Market Cap:
$76.25M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-5.6492
EPS:
-0.13
Net Cash Flow:
$-3.92M
1W Performance:
+1.30%
1M Performance:
-5.24%
6M Performance:
-13.60%
1Y Performance:
+25.93%
1-Day Range:
$0.71
$0.751
1-Week Range:
$0.68
$0.80
52-Week Range:
$0.41
$1.74
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
0.7344 | 76.25M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short Interest - MarketBeat
3 Penny Stocks In US With Market Caps Below $300M - Simply Wall St
Tiziana Life Sciences’ foralumab reduces side effects of discontinuing GLP-1 agonists - Proactive Investors USA
Tiziana reports progress in immunotherapy treatment - Investing.com India
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 - The Manila Times
Tiziana's Breakthrough Nasal Therapy Enhances GLP-1 Drug Benefits, Reduces Side Effects - StockTitan
Tiziana’s foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Nigeria
Tiziana's foralumab shows promise in neurodegenerative diseases By Investing.com - Investing.com Canada
Tiziana Life Sciences welcomes publication of article highlighting foralumab’s potential in neurological diseases - Proactive Investors UK
Tiziana's foralumab shows promise in neurodegenerative diseases - Investing.com India
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease - The Manila Times
Tiziana's Foralumab Shows Breakthrough Potential for Multiple Sclerosis in Nature Reviews Study - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short Interest - MarketBeat
Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis - Seeking Alpha
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia
Sanctuary Advisors LLC Makes New $864,000 Investment in Tiziana Life Sciences Ltd (NASDAQ:TLSA) - MarketBeat
Tiziana Life Sciences doses first Alzheimer’s patient with intranasal foralumab - Proactive Investors Australia
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Launches Novel Alzheimer's Treatment Trial with Groundbreaking Intranasal Therapy - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
3 US Penny Stocks With Market Caps Under $200M To Consider - Simply Wall St
17% Gain Today – This Stock Isn’t Done Yet - RagingBull
Tiziana Life Sciences expands Phase 2 trial for non-active SPMS - Yahoo Finance
Tiziana broadens Phase 2 trial for MS therapy By Investing.com - Investing.com Canada
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
PHLX Canadian Dollar (XDC) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Tiziana broadens Phase 2 trial for MS therapy - Investing.com India
S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions - Proactive Investors USA
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers - The Manila Times
Tiziana Life Sciences Expands Breakthrough MS Drug Trial to Elite U.S. Medical Centers - StockTitan
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7%Here's What Happened - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 3.7% – Here’s What Happened - Defense World
Elon Musk Says Amazon Founder Jeff Bezos Urged Tesla, SpaceX Investors To Dump Stakes, Predicting Trump's Loss - Benzinga
Tiziana Life Sciences Secures ALS Trial Funding - Yahoo Finance
Tiziana Life Sciences secures grant for ALS trial - Proactive Investors USA
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association - The Manila Times
Tiziana Life Sciences Secures ALS Association Grant for Breakthrough Foralumab Trial | TLSA Stock News - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short Interest - MarketBeat
Tiziana Life Sciences CEO discusses foralumab potential to enhance OzempicICYMI - Proactive Investors USA
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference - Proactive Investors UK
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - The Manila Times
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer’s therapy - Proactive Investors USA
Tiziana Life Sciences Plans Share Sale with Jefferies - MSN
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):